Fight the Fight Find the Cure
Breast Cancer is cancer which
develops from the breast tissue Signs of breast cancer may include a lump in
the breast, a change in breast shape, dimpling of the skin, fluid coming
from the nipple, or a red scaly patch of skin. In those with distant
spread of disease, there may be bone pain, swollen lymph
nodes, shortness of breath, or yellow skin.
Bisphosphonates
are commonly used in the treatment of osteoporosis and metastatic bone disease.
Their mechanism of action involves the inhibition of the osteoclast activity
leading to the reduction of bone resorption. Their activity reduces the
incidence of skeletal complications, such as fractures, pains, and
hypocalcaemia. Nowadays among the different Bisphosphonates Zoledronate is
largely used because of its relative higher potency and short infusion time.
Zoledronate is usually well tolerated; well known side effects of Zoledronate
include, fatigue, fever, myalgia or arthralgia, nausea, bone pains, and elevation
in serum creatinine .Retrospective studies have reported an association between
long-term Bisphosphonates therapy and osteonecrosis of the jaw .Ocular adverse
events have been reported with nitrogen-containing Bisphosphonates with unclear
underlying mechanisms. No ocular factors or predispositions are known. The
inflammations could be explained with the release of elevated levels of
cytokines, including tumor necrosis factor and interleukin 6.
Breast cancer
prevention starts with
healthy habits such as limiting alcohol and staying physically active some risk
factors, such as family history, can't be changed. However, there are lifestyle
changes you can make to lower your risk, Limit dose and duration of hormone therapy,
Avoid exposure to radiation and environmental pollution.
The world breast
cancer day was celebrated on October 20
every year on this many scientists and doctors will promote the awareness of
breast cancer and many programmers are conducted on this day to give hands to
the patients who suffering with breast cancer
0 comments: